Advertisement

Topics

Roche secures priority review from FDA for haemophilia A drug emicizumab

19:00 EDT 24 Aug 2017 | Pharmaceutical Business Review

Roche's emicizumab prophylaxis (preventative) has been granted priority review by the US Food and Drug Administration (FDA) for haemophilia A with factor VIII inhibitors.

Original Article: Roche secures priority review from FDA for haemophilia A drug emicizumab

NEXT ARTICLE

More From BioPortfolio on "Roche secures priority review from FDA for haemophilia A drug emicizumab"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...